Sana Biotechnology, Inc.’s SANA share price has dipped by 11.16%, which has investors questioning if this is right time to ...

UP421 is a primary human HIP-modified pancreatic islet cell therapy for patients with type 1 diabetes ... Dr. Patel has decades of experience in research, drug discovery, drug development, and ...

The prevalence of diabetes has alarmingly increased in both developed and developing countries in recent years. The ...

--(BUSINESS WIRE)--TIXiMED Inc. (www.tiximed.com), a clinical-stage pharmaceutical company based on the breakthrough discovery ... targeting beta cell health and islet cell function.

When tested in primary human beta cells, these molecular glues significantly reduced the toxic effects of glucolipotoxicity, thus preserving beta cell function and identity. This discovery ...

Islet cell transplantation is not a new concept ... power of science and innovation to transform lives. With each new ...

The work was supported in the United States by NIH/NIDDK R01DK130300 and the Human Islet and Adenoviral Core (HIAC) of P30DK020541, and in the European Union through ERC Advanced Grant PPI-Glue ...

Mitochondria act as cellular power plants, converting nutrients into energy. When these structures fail, cells struggle to ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Dr. Calias brings over two decades of global operational experience in drug product development from discovery to approval ... therapeutics combining its Cell Pouch with human donor cells or stem-cell ...

Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it's ...